SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing high volatility as traders debate whether recent drops signal a larger market correction or just a temporary pullback, fueled by concerns around AI valuations and potential recession indicators. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, closely watching key support levels and VIX movements. The conversation includes speculation about the Fed's next moves and the impact of economic data on market direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is trending down, sparking debate about an AI bubble. The community is actively discussing whether the drop is a market correction, profit-taking, or manipulation by institutional investors. Some also point to comments from a Fed official raising concerns about valuations as a contributing factor.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following a strong Q3 earnings report that included raised FY26 guidance and a surge in e-commerce sales, with discussion around its potential move to the Nasdaq. Community talking points include whether Walmart is a safe haven during market volatility and the impact of potential government shutdowns on SNAP benefits and consumer spending at Walmart stores.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant downturn, sparking debates about its role as a store of value and potential for further decline. Community discussions revolve around possible bottom levels, with some anticipating a substantial bounce while others fear a continued slide. The broader market context, including potential impacts from macroeconomic factors and liquidations, is also fueling uncertainty and volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MELI is experiencing a significant downturn, with discussions focusing on a recent shelf filing and potential competition from Amazon as possible catalysts. The community is expressing concerns about the stock's performance, with some seeing the dip as a buying opportunity while others are wary of further declines. Broader macroeconomic factors and regional risks in Latin America are also being considered as contributing factors to the volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to discussions around warrant redemptions and their impact on stock dilution, with a deadline approaching soon. The community is debating the company's long-term potential, its management, and comparing it to other rare earth companies, with some expressing concerns about recent performance and others highlighting its strategic partnerships and focus on heavy rare earth elements. News around the company's deal with Solvay and Saudi Arabian Mining Company (Maaden), meant to develop a rare earth refinery, has brought some recent attention.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as it hits fresh 52-week lows, with the community debating whether it's a buying opportunity or if further downside is expected due to its correlation with Bitcoin. Despite the recent price drop, some traders are noting unusual call option activity, suggesting contrarian bullish bets, while others point to potential liquidation levels and debt concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Sells 3,726 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Lauren Merendino sold 3,726 shares of the company's stock in a transaction on Monday, November 17th. The stock was sold at an...

Day One Biopharmaceuticals (NASDAQ:DAWN) CFO Sells 4,062 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles York II sold 4,062 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an...

Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Adam Dubow Sells 4,319 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Adam Dubow sold 4,319 shares of the company's stock in a transaction dated Monday, November 17th. The stock was sold at an...

Jeremy Bender Sells 15,894 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CEO Jeremy Bender sold 15,894 shares of the business's stock in a transaction that occurred on Monday, November 17th. The shares were...

Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 161.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Day One Biopharmaceuticals Sees Unusually Large Options Volume (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock investors purchased 3,055 call options on the stock. This is...

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Here's Why

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Time to Sell...

<ul class="summary-bullets"><li>Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.</li><li>Analysts said competing bids are unlikely and noted Day One’s offer reflects confidence in Mersana’s assets.</li><li>Retail traders called the deal a bargain for Day One and highlighted Mersana’s broader pipeline value.</li></ul>Mersana Therapeutics logged its strongest trading session on record on Thursday, soaring even as a long list of Wall Street firms downgraded the stock after Day One Biopharmaceuticals agreed to acquire the company in a deal that could be worth up to $285 million.Day One Biopharmaceuticals closed down 14% on Thursday, while Mersana Therapeutics finished the session up 209%.<h2 class="st-heading-2">Analysts Weigh In On Day One’s Bid</h2>William Blair downgraded Mersana to ‘Market Perform’ from ‘Outperform’, saying it views it as unlikely that another bidder will emerge.Guggenheim cut its rating to ‘Neutral’ from ‘Buy’, while LifeSci Capital shifted its view to ‘Market Perform’ from ‘Outperform.’ Leerink moved the stock to ‘Market Perform’ from ‘Outperform’ and set a $29 price target. Truist downgraded Mersana to ‘Hold’ from ‘Buy’ and lowered its target to $30.75 from $36, saying it believes the deal will go through and estimating the CVR’s value at $5.75. BTIG lowered its rating to ‘Neutral’ from ‘Buy’, and Wedbush also cut the stock to ‘Neutral’ from ‘Outperform.’Oppenheimer said Day One paying up to $285 million for Mersana “is interesting.” The firm noted the acquisition “wasn't on the short list,” and said management had been “talking down PTK7,” and questioned whether Emi-Le may be positioned as its replacement. Oppenheimer added that Day One could have obtained a comparable asset from China at a lower cost and said the offer suggests management is “seeing something in Emi-Le.” The firm reiterated a ‘Perform’ rating on Day One.<h2 class="st-heading-2">Deal Terms</h2>Under the merger agreement, Day One will launch a tender offer within 10 business days of Nov. 12. The deal requires that a majority of Mersana’s shares be tendered for the transaction to proceed, after which any remaining shares would be acquired in a follow-on merger for the same consideration. Once completed, Mersana would become a wholly owned subsidiary of Day One, and its stock would be delisted.&nbsp;The agreement received unanimous board approval, and holders representing about 8.5% of outstanding shares, including executives, directors, and Bain Capital Life Sciences affiliates, have signed support agreements to tender their shares.<h2 class="st-heading-2">Legal Review</h2>Separately, law firm Ademi &amp; Fruchter said it is reviewing the deal for potential breaches of fiduciary duty, citing insider benefits, deal protection,s and limits on competing offers.<h2 class="st-heading-2">Stocktwits Traders Flag ‘Cheap’ Valuations</h2>On Stocktwits, retail sentiment for both Mersana and Day One was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said, “If they were able to buy Mersana Therapeutics ($MRSN), they could easily buy $CHRS; I'm sure many companies are interested, it's very cheap.”<stembedurl>https://stocktwits.com/Sarandon/message/636088418</stembedurl>Another user argued that Day One is getting what they called “a very good bargain” in the acquisition, saying the company is “effectively getting the entire pipeline of Mersana for about $40 million” and adding, “I am buying the stock.”<stembedurl>https://stocktwits.com/Itinerant/message/636101103</stembedurl>A third user noted that while many investors had expected Day One to be a buyout target, in this deal the company instead acted as “Apex predator,” adding that it would be “interesting to watch further manifestations in this new constitution.”<stembedurl>https://stocktwits.com/GeniusLoci/message/636078018</stembedurl><a href="https://stocktwits.com/symbol/MRSN">Mersana’s stock</a> has more than tripled so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One’s stock</a> has climbed 35% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mersana’s stock (MRSN) has more than tripled so far in 2025, while Day One’s stock (DAWN) has climbed 35% over the same period. (Photo credit: Getty Images)

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Equity

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.read more...

Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

DAWN
Day One Biopharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DAWN News

DAWNDay One Biopharmaceuticals Inc